The steroid receptor RNA activator protein (SRAP) controls cancer cell migration/motility

Yan, Yongping; Cooper, Charlton; Hamedani, Mohammad K.; Guppy, Brent J.; Xu, Wayne; Tsuyuki, Deborah; Zhang, Christine; Nugent, Zoann; Blanchard, Anne; Davie, James R.; McManus, Kirk J.; Murphy, Leigh C.; Myal, Yvonne; Leygue, Etienne

doi:10.1016/j.febslet.2015.11.007

Cited by 13 publications

(7 citation statements)

References 30 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deep-sequencing experiments revealed many examples of genes producing both protein-coding and noncoding transcripts by alternative splicing. However, so far, only very few reports demonstrate a functional role for both the noncoding RNA(s) and the protein(s) encoded by transcripts derived from the same gene [ 15 , 16 ]. It is tempting to speculate that such dual usage of transcripts is more frequent than anticipated.…”

Section: Introductionmentioning

confidence: 99%

Mechanisms of long noncoding RNA function in development and disease

Schmitz

Grote

Herrmann

2016

Cell. Mol. Life Sci.

929

627

View full text Add to dashboard Cite

Since decades it has been known that non-protein-coding RNAs have important cellular functions. Deep sequencing recently facilitated the discovery of thousands of novel transcripts, now classified as long noncoding RNAs (lncRNAs), in many vertebrate and invertebrate species. LncRNAs are involved in a wide range of cellular mechanisms, from almost all aspects of gene expression to protein translation and stability. Recent findings implicate lncRNAs as key players of cellular differentiation, cell lineage choice, organogenesis and tissue homeostasis. Moreover, lncRNAs are involved in pathological conditions such as cancer and cardiovascular disease, and therefore provide novel biomarkers and pharmaceutical targets. Here we discuss examples illustrating the versatility of lncRNAs in gene control, development and differentiation, as well as in human disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Mechanisms of long noncoding RNA function in development and disease

Schmitz

Grote

Herrmann

2016

Cell. Mol. Life Sci.

929

627

View full text Add to dashboard Cite

show abstract

“…As it was mentioned, SRA1 is a nuclear receptor that encodes both non-coding (lncRNA SRA1) and coding (SRAP) products result from alternative splicing 7,8,10. It is believed that both transcripts are functional and regulate several molecular pathways especially through ERs 7,9,11.…”

Section: Discussionmentioning

confidence: 99%

“…Each PCR reaction comprised of 10 µl 2X RealQ-PCR Master Mix ® (Ampliqon, Odense, Denmark), 1 µl cDNA (≥10 ng), 0.5 µl of each primer (5 pmol) and 7 µl of nuclease-free water in a total volume of 20 µl reaction mixture. Primers for amplification of SRA1 lncRNA were obtained from a previous study 8…”

Section: Methodsmentioning

confidence: 99%

<p>LncRNA SRA1 may play a role in the uterine leiomyoma tumor growth regarding the <em>MED12</em> mutation pattern</p>

Akbari

Yassaee

Amin-Beidokhti

et al. 2019

IJWH

View full text Add to dashboard Cite

Background Uterine leiomyomas (ULMs) are benign uterine tumors that are estrogen-dependent. Recent studies suggest that the abnormal expression of the steroid receptor RNA activator 1 (SRA1) long non-coding RNA (lncRNA) might participate in the mechanisms of tumorigenesis of some hormone-dependent tumors including breast cancer. SRA1 is known to enhance the transcriptional activity of steroid receptors and also promotes steroidogenesis. The level of steroid hormones, such as estrogen and the progesterone, and their receptors play an important role in the development and growth of leiomyoma. The aim of the present study was to determine the expression level of lncRNA SRA1 in ULM tissues considering the MED12 mutation pattern. Methods Mutation screening was performed for MED12 exons 1 and 2 and the intronic flanking regions using Sanger sequencing in 60 ULM tissues. Quantitative real-time polymerase chain reaction (qRT-PCRs) was performed in order to estimate the expression of lncRNA SRA1 in leiomyoma samples with and without MED12 gene mutations. The expression results were analyzed by using LinReg and REST software. Results Mutations were detected in exon 2 of the MED12 in 28 (46.67%) ULM samples; including, 21 (75%) missense mutations and 7 (25%) in-frame deletions. No mutation was detected in the MED12 exon 1. LncRNA SRA1 was over-expressed in ULM samples without MED12 mutation compared with ULM samples harboring MED12 mutation (Expression ratio=2.5, P -value=0.004). Conclusion Present results suggest that lncRNA SRA1 may explain the phenotypic difference observed in the tumor size of ULM samples considering MED12 mutation pattern. Therefore, it serves as a good therapeutic target and provides new insight into understanding the disease molecular mechanism.

show abstract

“…In contrast, SRAP levels were significantly higher in ERα-positive and PR-positive breast cancer biopsies, identifying SRAP as a potential new prognostic marker for breast cancer patients ( 84 ). A recent study further indicated that overexpressing SRAP increases breast cancer cell motility ( 85 ).…”

Section: Sra and Human Diseasementioning

confidence: 99%

New Insights Into the Long Non-coding RNA SRA: Physiological Functions and Mechanisms of Action

Sheng

Zhang

et al. 2018

Front. Med.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNA) are emerging as new genetic/epigenetic regulators that can impact almost all physiological functions. Here, we focus on the long non-coding steroid receptor RNA activator (SRA), including new insights into its effects on gene expression, the cell cycle, and differentiation; how these relate to physiology and disease; and the mechanisms underlying these effects. We discuss how SRA acts as an RNA coactivator in nuclear receptor signaling; its effects on steroidogenesis, adipogenesis, and myocyte differentiation; the impact on breast and prostate cancer tumorigenesis; and, finally, its ability to modulate hepatic steatosis through several signaling pathways. Genome-wide analysis reveals that SRA regulates hundreds of target genes in adipocytes and breast cancer cells and binds to thousands of genomic sites in human pluripotent stem cells. Recent studies indicate that SRA acts as a molecular scaffold and forms networks with numerous coregulators and chromatin-modifying regulators in both activating and repressive complexes. We discuss how modifications to SRA's unique stem-loop secondary structure are important for SRA function, and highlight the various SRA isoforms and mutations that have clinical implications. Finally, we discuss the future directions for better understanding the molecular mechanisms of SRA action and how this might lead to new diagnostic and therapeutic approaches.

show abstract

The steroid receptor RNA activator protein (SRAP) controls cancer cell migration/motility

Cited by 13 publications

References 30 publications

Mechanisms of long noncoding RNA function in development and disease

Mechanisms of long noncoding RNA function in development and disease

<p>LncRNA SRA1 may play a role in the uterine leiomyoma tumor growth regarding the <em>MED12</em> mutation pattern</p>

New Insights Into the Long Non-coding RNA SRA: Physiological Functions and Mechanisms of Action

Contact Info

Product

Resources

About